cbd script

When making an application to the TGA, you will need to reference clinical evidence that supports using the specific type of medicinal cannabis product proposed (e.g. THC, CBD, or THC and CBD in combination) for your patient’s medical condition or symptoms.

Clinicians should not:

Clinical evidence

NSW Cannabis Medicines Advisory Service – (for NSW health practitioners only). However, the Service is also available if:

Your legal obligations

Medicinal cannabis products are classified as either Schedule 3, Schedule 4 or Schedule 8 controlled substances, most products are not listed on the Australian Register of Therapeutic Goods (ARTG). In circumstances where patients need access to therapeutic goods that are not included in the ARTG, a Therapeutic Goods Administration (TGA) approval is required in order for the medicine to be prescribed.

All products not registered on the ARTG require approval from the Commonwealth Therapeutic Goods Administration (TGA) to be prescribed. This approval can be obtained through either the TGA’s Special Access Scheme

Who can prescribe medicinal cannabis?

Medicinal cannabis refers to quality-assured pharmaceutical products that use the cannabis plant or chemicals contained within it to treat medical conditions, and are only available via prescription. There are over 100 cannabinoids in the cannabis plant. The two main cannabinoids that have been studied for potential therapeutic effects are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). As a result, medicinal cannabis products available in Australia tend to contain mostly THC, mostly CBD or a combination of both in their formulations. Some products also contain other chemical components from the cannabis plant including additional cannabinoids, terpenes and flavonoids.

Product types

Medicinal cannabis does not include the recreational or self-described medical use of cannabis without a prescription, both of which remain illegal in Victoria.